These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 23553901)
1. Efficacy comparison of traditional Chinese medicine LQ versus gemcitabine in a mouse model of pancreatic cancer. Zhang L; Wu C; Zhang Y; Liu F; Zhao M; Bouvet M; Hoffman RM J Cell Biochem; 2013 Sep; 114(9):2131-7. PubMed ID: 23553901 [TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy and toxicity of traditional Chinese medicine (TCM) herbal mixture LQ and conventional chemotherapy on lung cancer metastasis and survival in mouse models. Zhang L; Wu C; Zhang Y; Liu F; Wang X; Zhao M; Hoffman RM PLoS One; 2014; 9(10):e109814. PubMed ID: 25286158 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). Hiroshima Y; Zhao M; Maawy A; Zhang Y; Katz MH; Fleming JB; Uehara F; Miwa S; Yano S; Momiyama M; Suetsugu A; Chishima T; Tanaka K; Bouvet M; Endo I; Hoffman RM J Cell Biochem; 2014 Jul; 115(7):1254-61. PubMed ID: 24435915 [TBL] [Abstract][Full Text] [Related]
5. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046 [TBL] [Abstract][Full Text] [Related]
6. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. Katz MH; Takimoto S; Spivack D; Moossa AR; Hoffman RM; Bouvet M J Surg Res; 2003 Jul; 113(1):151-60. PubMed ID: 12943825 [TBL] [Abstract][Full Text] [Related]
7. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. Kawaguchi K; Miyake K; Zhao M; Kiyuna T; Igarashi K; Miyake M; Higuchi T; Oshiro H; Bouvet M; Unno M; Hoffman RM Cell Cycle; 2018; 17(16):2019-2026. PubMed ID: 29963961 [TBL] [Abstract][Full Text] [Related]
8. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922 [TBL] [Abstract][Full Text] [Related]
10. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869 [TBL] [Abstract][Full Text] [Related]
11. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer. Hiroshima Y; Maawy AA; Katz MH; Fleming JB; Bouvet M; Endo I; Hoffman RM J Surg Oncol; 2015 Mar; 111(3):311-5. PubMed ID: 25394368 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Sun FX; Tohgo A; Bouvet M; Yagi S; Nassirpour R; Moossa AR; Hoffman RM Cancer Res; 2003 Jan; 63(1):80-5. PubMed ID: 12517781 [TBL] [Abstract][Full Text] [Related]
13. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy. Sugisawa N; Miyake K; Higuchi T; Oshiro H; Zhang Z; Park JH; Kawaguchi K; Chawla SP; Bouvet M; Singh SR; Unno M; Hoffman RM Anticancer Res; 2019 Oct; 39(10):5339-5344. PubMed ID: 31570427 [TBL] [Abstract][Full Text] [Related]
14. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Ammons WS; Wang JW; Yang Z; Tidmarsh GF; Hoffman RM Neoplasia; 2007 Aug; 9(8):625-33. PubMed ID: 17786181 [TBL] [Abstract][Full Text] [Related]
15. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918 [TBL] [Abstract][Full Text] [Related]
16. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081 [TBL] [Abstract][Full Text] [Related]
17. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887 [TBL] [Abstract][Full Text] [Related]
18. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642 [TBL] [Abstract][Full Text] [Related]
19. Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model. Dai X; Liu D; Liu M; Zhang X; Wang W; Jin F; Qian Y; Wang X; Zhao J; Wu Y; Xiong F; Chang NA; Sun YU; Yang Z; Hoffman RM; Liu Y Anticancer Res; 2017 Mar; 37(3):979-986. PubMed ID: 28314255 [No Abstract] [Full Text] [Related]
20. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Iwanski GB; Lee DH; En-Gal S; Doan NB; Castor B; Vogt M; Toh M; Bokemeyer C; Said JW; Thoennissen NH; Koeffler HP Br J Pharmacol; 2010 Jun; 160(4):998-1007. PubMed ID: 20590594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]